{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:44:07Z","timestamp":1792449847818,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jaad.2016.07.065","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T19:01:38Z","timestamp":1487703698000},"page":"393-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":208,"title":["Psoriasis and comorbid diseases"],"prefix":"10.1016","volume":"76","author":[{"given":"Junko","family":"Takeshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungat","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin\u00e9ad M.","family":"Langan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal N.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby S.","family":"Van Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.07.065_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaad.2011.09.006","article-title":"Are patients with psoriasis being screened for cardiovascular risk factors? A study of screening practices and awareness among primary care physicians and cardiologists","volume":"67","author":"Parsi","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2011.06.035","article-title":"Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis","volume":"67","author":"Kimball","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/jamadermatol.2014.2094","article-title":"Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom","volume":"151","author":"Takeshita","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib4","first-page":"e14","article-title":"Psoriasis and cardiovascular screening rates in the United States","volume":"12","author":"Alamdari","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2015.07.029","article-title":"Survey of trends and gaps in dermatologists' cardiovascular screening practices in psoriasis patients: areas still in need of improvement","volume":"73","author":"Manalo","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib6","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.amjcard.2008.10.004","article-title":"AJC editor's consensus: psoriasis and coronary artery disease","volume":"102","author":"Friedewald","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaad.2016.07.065_bib7","first-page":"1031","article-title":"National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening","volume":"58","author":"Kimball","year":"2008","journal-title":"J Drugs Dermatol"},{"issue":"25 suppl 2","key":"10.1016\/j.jaad.2016.07.065_bib8","first-page":"S76","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Eckel","year":"2014","journal-title":"Circulation"},{"issue":"25 pt B","key":"10.1016\/j.jaad.2016.07.065_bib9","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaad.2016.07.065_bib10","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jaad.2012.05.016","article-title":"The impact of psoriasis on 10-year Framingham risk","volume":"67","author":"Mehta","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2016.07.065_bib12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2007.06.042","article-title":"Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey","volume":"57","author":"Horn","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib13","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey","volume":"70","author":"Lebwohl","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.HYP.16.4.472","article-title":"Reminiscences of the Veterans Administration trial of the treatment of hypertension","volume":"16","author":"Freis","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.jaad.2016.07.065_bib16","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group","volume":"265","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2016.07.065_bib17","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaad.2016.07.065_bib18","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jaad.2016.07.065_bib19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2016.07.065_bib20","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2796.2012.02593.x","article-title":"Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study","volume":"273","author":"Ahlehoff","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaad.2016.07.065_bib22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaad.2004.06.017","article-title":"Methotrexate reduces\u00a0incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis","volume":"52","author":"Prodanovich","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib23","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1365-2133.2011.10525.x","article-title":"The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study","volume":"165","author":"Abuabara","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib24","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/art.34335","article-title":"Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study","volume":"64","author":"Chen","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2016.07.065_bib25","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-2133.2011.10652.x","article-title":"Psoriasis and cardiovascular disease: an association or a reason to treat?","volume":"165","author":"Margolis","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib26","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(11)61383-4","article-title":"Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial","volume":"378","author":"Fayad","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2016.07.065_bib27","first-page":"e3777","article-title":"Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography\/computed tomography (FDG-PET\/CT)","author":"Mehta","year":"2012","journal-title":"J Vis Exp"},{"key":"10.1016\/j.jaad.2016.07.065_bib28","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1161\/CIRCULATIONAHA.112.120410","article-title":"Anti-tumor necrosis factor-alpha therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis","volume":"126","author":"Maki-Petaja","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jaad.2016.07.065_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/CIRCIMAGING.112.975730","article-title":"Effects of the tumor necrosis factor-alpha antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial","volume":"6","author":"Bissonnette","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2016.07.065_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1538-7836.2009.03404.x","article-title":"Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)","volume":"7","author":"Ridker","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jaad.2016.07.065_bib31","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ijo.2015.64","article-title":"Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis","volume":"39","author":"Upala","year":"2015","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jaad.2016.07.065_bib32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaad.2007.11.011","article-title":"The effect of weight on the efficacy of biologic therapy in patients with psoriasis","volume":"58","author":"Clark","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib33","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","article-title":"Obesity and psoriasis: body weight and body mass index influence the response to biological treatment","volume":"25","author":"Puig","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2016.07.065_bib34","first-page":"S50","article-title":"Factors associated with being clear\/almost clear of psoriasis in patients receiving adalimumab, etanercept, or methotrexate as part of routine clinical care","volume":"134","author":"Hong","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib35","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1517\/14712598.2014.900541","article-title":"The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial","volume":"14","author":"Al-Mutairi","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaad.2016.07.065_bib36","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3945\/ajcn.2008.26427","article-title":"Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial","volume":"88","author":"Gisondi","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jaad.2016.07.065_bib37","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/archderm.141.12.1527","article-title":"Impact of obesity and smoking on psoriasis presentation and management","volume":"141","author":"Herron","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib38","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2008.11.906","article-title":"Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference","volume":"60","author":"Kalb","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib39","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1046\/j.1440-1746.2001.02644.x","article-title":"Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury","volume":"16","author":"Langman","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","article-title":"Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment","volume":"46","author":"Rosenberg","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib41","doi-asserted-by":"crossref","first-page":"778","DOI":"10.7326\/M15-2223","article-title":"US Preventative Services Task Force. Screening for high blood pressure in adults: US Preventive Services Task Force Recommendation Statement","volume":"163","author":"Siu","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2016.07.065_bib42","doi-asserted-by":"crossref","first-page":"e18227","DOI":"10.1371\/journal.pone.0018227","article-title":"Psoriasis and hypertension severity: results from a case-control study","volume":"6","author":"Armstrong","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jaad.2016.07.065_bib43","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2009.05.017","article-title":"Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference","volume":"62","author":"Rosmarin","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib44","unstructured":"US Preventative Services Task Force. Abnormal blood glucose and type 2 diabetes mellitus: screening 2015. Available from: URL: http:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/RecommendationStatementFinal\/screening-for-abnormal-blood-glucose-and-type-2-diabetes#Pod2. Accessed March 19, 2016."},{"issue":"suppl 1","key":"10.1016\/j.jaad.2016.07.065_bib45","first-page":"S14","article-title":"Standards of medical care in diabetes\u20132014","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"issue":"suppl","key":"10.1016\/j.jaad.2016.07.065_bib46","first-page":"S4","article-title":"Standards of medical care in diabetes\u20132015: summary of revisions","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2016.07.065_bib47","first-page":"S1","article-title":"Standards of medical care in diabetes - 2015","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaad.2016.07.065_bib48","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/archdermatol.2012.1401","article-title":"Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis","volume":"148","author":"Azfar","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib49","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jaad.2015.02.1095","article-title":"Psoriasis and\u00a0risk of diabetes-associated microvascular and macrovascular complications","volume":"72","author":"Armstrong","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib50","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: a population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib51","first-page":"300","article-title":"Serum lipid changes during acitretin (etretin) treatment of psoriasis and palmo-plantar pustulosis","volume":"68","author":"Vahlquist","year":"1988","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.07.065_bib52","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2016.07.065_bib53","unstructured":"Secukinumab [package insert]. Available at: URL: http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/cosentyx.pdf. Accessed November 22, 2015."},{"key":"10.1016\/j.jaad.2016.07.065_bib54","unstructured":"Ixekizumab [package insert]. Available at: URL: http:\/\/pi.lilly.com\/us\/taltz-uspi.pdf. Accessed April 9, 2016."},{"key":"10.1016\/j.jaad.2016.07.065_bib55","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/bjd.12905","article-title":"Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis","volume":"170","author":"Maybury","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib56","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1053\/j.gastro.2008.08.057","article-title":"A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis","volume":"135","author":"Boetticher","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2016.07.065_bib57","doi-asserted-by":"crossref","first-page":"f5961","DOI":"10.1136\/bmj.f5961","article-title":"Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study","volume":"347","author":"Wan","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2016.07.065_bib58","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jdermsci.2015.03.012","article-title":"Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: a nationwide population-based cohort study","volume":"78","author":"Chi","year":"2015","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2016.07.065_bib59","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/jid.2009.113","article-title":"Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis","volume":"129","author":"Brauchli","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib60","first-page":"778","article-title":"The risk of malignancy associated with psoriasis","volume":"137","author":"Margolis","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib61","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2016.07.065_bib62","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies","volume":"27","author":"Pouplard","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.07.065_bib63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaad.2016.07.065_bib64","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries\u00a0and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2016.07.065_bib65","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2016.07.065_bib66","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/archderm.134.12.1582","article-title":"Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis","volume":"134","author":"Stern","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib67","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2133.2008.08776.x","article-title":"Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy","volume":"159","author":"Hearn","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib68","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jaad.2016.07.065_bib69","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2016.07.065_bib70","first-page":"CD005414","article-title":"Interventions for preventing non-melanoma skin cancers in high-risk groups","author":"Bath-Hextall","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2016.07.065_bib71","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/cncr.26374","article-title":"Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)","volume":"118","author":"Kadakia","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2016.07.065_bib72","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jaad.2010.08.036","article-title":"Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort","volume":"65","author":"Wakkee","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"5 suppl 1","key":"10.1016\/j.jaad.2016.07.065_bib73","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jid.2016.02.219","article-title":"Increased risk of serious infection among patients with psoriasis: a population-based cohort study in the United Kingdom","volume":"136","author":"Takeshita","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2016.07.065_bib74","doi-asserted-by":"crossref","first-page":"e116077","DOI":"10.1371\/journal.pone.0116077","article-title":"Psoriasis and the risk of pneumonia: a population-based study","volume":"9","author":"Kao","year":"2014","journal-title":"PLoS ONE"},{"issue":"5S, Suppl 1","key":"10.1016\/j.jaad.2016.07.065_bib75","first-page":"S50","article-title":"Increased risk of\u00a0pneumonia among patients with psoriasis: a population-based cohort study in the United Kingdom","volume":"135","author":"Takeshita","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib76","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib77","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2016.07.065_bib78","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamadermatol.2014.4956","article-title":"Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study","volume":"151","author":"Shalom","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib79","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaad.2013.06.046","article-title":"From the Medical Board of the National Psoriasis Foundation: vaccination in adult patients on systemic therapy for psoriasis","volume":"69","author":"Wine-Lee","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"64","key":"10.1016\/j.jaad.2016.07.065_bib80","first-page":"93","article-title":"Advisory committee on immunization practices recommended immunization schedules for persons aged 0 through 18 years\u2013United States, 2015","author":"Strikas","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"64","key":"10.1016\/j.jaad.2016.07.065_bib81","first-page":"91","article-title":"Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older\u2013United States, 2015","author":"Kim","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2016.07.065_bib82","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaad.2016.07.065_bib83","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaad.2013.08.049","article-title":"From the Medical Board of the National Psoriasis Foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis","volume":"70","author":"Motaparthi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib84","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guidelines for the management of rheumatoid arthritis: 2002 Update","volume":"46","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2016.07.065_bib85","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/j.1440-1746.2006.04559.x","article-title":"Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach","volume":"21","author":"Nathan","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib86","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009","volume":"161","author":"Smith","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib87","first-page":"1","article-title":"Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings","volume":"55","author":"Branson","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaad.2016.07.065_bib88","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2016.07.065_bib89","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2016.07.065_bib90","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib91","first-page":"891","article-title":"The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study","volume":"146","author":"Kurd","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib92","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/bjd.14032","article-title":"Risk of depression in women with psoriasis: a cohort study","volume":"173","author":"Dommasch","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib93","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202641","article-title":"Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials","volume":"73","author":"Goulabchand","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2016.07.065_bib94","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2016.07.065_bib95","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2016.07.065_bib96","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis: treatment recommendations for psoriatic arthritis 2015","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2016.07.065_bib97","doi-asserted-by":"crossref","first-page":"783","DOI":"10.7326\/0003-4819-147-11-200712040-00009","article-title":"Screening for high blood pressure: US Preventative Task Force reaffirmation recommendation statement","volume":"147","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2016.07.065_bib98","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc14-S014","article-title":"Standards of medical care in diabetes--2014","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaad.2016.07.065_bib99","doi-asserted-by":"crossref","first-page":"716","DOI":"10.7326\/0003-4819-151-10-200911170-00008","article-title":"Screening for breast cancer: US Preventive Services Task Force recommendation statement","volume":"151","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2016.07.065_bib100","doi-asserted-by":"crossref","first-page":"880","DOI":"10.7326\/0003-4819-156-12-201206190-00424","article-title":"Screening for\u00a0cervical cancer: US Preventive Services Task Force recommendation statement","volume":"156","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2016.07.065_bib101","doi-asserted-by":"crossref","first-page":"627","DOI":"10.7326\/0003-4819-149-9-200811040-00243","article-title":"Screening for colorectal cancer: US Preventive Services Task Force recommendation statement","volume":"149","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2016.07.065_bib102","doi-asserted-by":"crossref","first-page":"330","DOI":"10.7326\/M13-2771","article-title":"US Preventative Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement","volume":"160","author":"Moyer","year":"2014","journal-title":"Ann Intern Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216306272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216306272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:41:52Z","timestamp":1759272112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216306272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0190962216306272"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.07.065","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis and comorbid diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.07.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(17)30096-8","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}